Evidence map›Paper›PMID 22174295›Full record

ArticlePacific Symposium on Biocomputing. Pacific Symposium on Biocomputing2012

Integrating VA's NDF-RT drug terminology with PharmGKB: preliminary results.

Jyotishman Pathak, Laura C Weiss, Matthew J Durski, Qian Zhu, Robert R Freimuth, Christopher G Chute

Abstract read
In one paragraph

Article in Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jyotishman PathakDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. pathak.jyotishman@mayo.edu
Laura C Weiss
Matthew J Durski
Qian Zhu
Robert R Freimuth
Christopher G Chute

Funding

Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
PHARMACOGENETICS OF PHASE II DRUG METABOLIZING ENZYMESU01GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2000 to 2009
$15.7M
National Infrastructure for Standardized and Portable EHR Phenotyping AlgorithmsR01GM105688 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI LUO, YUAN, PATHAK, JYOTISHMAN · 2013 to 2020
$5.7M
NIGMS NIH HHS R01 GM105688NIGMS NIH HHS U01 GM061388NIGMS NIH HHS U01GM061388NIGMS NIH HHS U19 GM061388
6 · The paper itself

Abstract

Biomedical terminology and vocabulary standards play an important role in enabling consistent, comparable, and meaningful sharing of data within and across institutional boundaries, as well as ensuring semantic interoperability. The Veterans Affairs (VA) National Drug File Reference Terminology (NDF-RT) is a federally recommended standardized terminology resource encompassing medications, ingredients, and a hierarchy for high-level drug classes. In this study, we investigate the drug-disease relationships in NDF-RT and determine how PharmGKB can be leveraged to augment NDF-RT, and vice-versa. Our preliminary results indicate that with additional curation and analyses, information contained in both knowledge resources can be mutually integrated.

Indexed as

Knowledge BasesPharmaceutical PreparationsComputational BiologyDiseaseDrug TherapyHumansPharmacogeneticsPharmacokineticsTerminology as TopicUnited StatesUnited States Department of Veterans AffairsPharmaceutical Preparations

Identifiers

PMID22174295
PMCPMC3909655

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.